Xeris Biopharma Holdings Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Xeris Biopharma Holdings Inc 公司

Xeris Biopharma Holdings, Inc. 是一家生物製藥公司，致力於通過開發和商業化一系列治療產品來改善患者的生活。該公司有三種商業產品。Gvoke 是一種即用型液體穩定型胰高血糖素，用於治療嚴重低血糖症。Recorlev 是一種皮質醇合成抑制劑，獲准用於治療無法進行手術或無法治癒的庫欣綜合徵成年患者的內源性皮質醇增多症。Keveyis 是美國首個獲批用於治療高鉀血癥、低鉀血癥和原發性週期性麻痹 (PPP) 相關變體的療法。該公司還擁有一系列開發項目，利用其專有的配方科學 XeriSol 和 XeriJect 推出新產品。其候選產品 XP-8121 旨在每週注射一次，小劑量，皮下注射，繞過胃腸道，可以避免許多治療併發症。

Xeris Biopharma Holdings Inc簡介



公司代碼XERS

公司名稱Xeris Biopharma Holdings Inc

上市日期Jun 21, 2018

CEOMr. John P. Shannon

員工數量394

證券類型Ordinary Share

年結日Jun 21

公司地址1375 West Fulton Street, Suite 1300

城市CHICAGO

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編60607

電話18444455704

網址https://www.xerispharma.com/

公司代碼XERS

上市日期Jun 21, 2018

CEOMr. John P. Shannon

Xeris Biopharma Holdings Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Kevin McCulloch

President, Chief Operating Officer

922.37K

-0.08%

Ms. Beth P. Hecht, J.D.

Chief Legal Officer, Corporate Secretary

513.93K

+80.45%

Dr. Jeffrey W. Sherman, M.D.

Independent Director

174.59K

+2.83%

Dr. Garheng Kong, M.D., Ph.D.

Independent Director

164.14K

+43.80%

Ms. Marla S. Persky, J.D.

Independent Chairman of the Board

98.37K

-13.61%

Ms. Dawn Halkuff

Independent Director

70.41K

-37.64%

Mr. Steven M. Pieper

Chief Financial Officer

--

Mr. James Brady

Independent Director

--

Mr. John P. Shannon

Chief Executive Officer, Director

--

Ms. Allison Wey

Senior Vice President - Investor Relations & Corporate Communications

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Kevin McCulloch

President, Chief Operating Officer

922.37K

-0.08%

Ms. Beth P. Hecht, J.D.

Chief Legal Officer, Corporate Secretary

513.93K

+80.45%

Dr. Jeffrey W. Sherman, M.D.

Independent Director

174.59K

+2.83%

Dr. Garheng Kong, M.D., Ph.D.

Independent Director

164.14K

+43.80%

Ms. Marla S. Persky, J.D.

Independent Chairman of the Board

98.37K

-13.61%

Ms. Dawn Halkuff

Independent Director

70.41K

-37.64%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

業務USD

名稱

營收

佔比

Product revenue -Recorlev

31.44M

43.95%

Product revenue - Gvoke

23.47M

32.80%

Product revenue - Keveyis

11.48M

16.05%

Royalty, contract and other revenue

3.83M

5.36%

Other product revenue

1.31M

1.83%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

Product revenue -Recorlev

31.44M

43.95%

Product revenue - Gvoke

23.47M

32.80%

Product revenue - Keveyis

11.48M

16.05%

Royalty, contract and other revenue

3.83M

5.36%

Other product revenue

1.31M

1.83%

股東統計

更新時間: 8月18日週一

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

6.29%

The Vanguard Group, Inc.

6.08%

D. E. Shaw & Co., L.P.

2.38%

State Street Investment Management (US)

2.34%

Geode Capital Management, L.L.C.

2.26%

其他

80.65%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

6.29%

The Vanguard Group, Inc.

6.08%

D. E. Shaw & Co., L.P.

2.38%

State Street Investment Management (US)

2.34%

Geode Capital Management, L.L.C.

2.26%

其他

80.65%

股東類型

持股股東

佔比

Investment Advisor

21.48%

Investment Advisor/Hedge Fund

16.59%

Hedge Fund

13.62%

Research Firm

4.38%

Individual Investor

4.04%

Pension Fund

0.43%

Sovereign Wealth Fund

0.35%

Bank and Trust

0.10%

Family Office

0.07%

其他

38.94%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

350

91.94M

56.94%

-7.04M

2025Q2

336

95.54M

59.64%

+13.83M

2025Q1

335

93.86M

58.93%

+12.36M

2024Q4

297

71.87M

48.21%

-8.26M

2024Q3

280

71.79M

48.23%

-5.89M

2024Q2

269

66.65M

44.99%

-10.81M

2024Q1

284

69.70M

49.68%

-4.28M

2023Q4

271

65.59M

47.45%

-7.22M

2023Q3

264

62.48M

45.27%

-15.54M

2023Q2

276

65.86M

49.56%

-15.25M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

10.16M

6.29%

+561.21K

+5.85%

Jun 30, 2025

The Vanguard Group, Inc.

9.82M

6.08%

+1.71M

+21.05%

Jun 30, 2025

D. E. Shaw & Co., L.P.

3.84M

2.38%

+783.03K

+25.65%

Jun 30, 2025

State Street Investment Management (US)

3.78M

2.34%

+457.94K

+13.77%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.65M

2.26%

+244.86K

+7.19%

Jun 30, 2025

Qube Research & Technologies Ltd

3.09M

1.91%

+1.25M

+67.51%

Jun 30, 2025

Millennium Management LLC

2.93M

1.82%

+615.65K

+26.56%

Jun 30, 2025

Morgan Stanley & Co. LLC

2.61M

1.62%

-532.53K

-16.93%

Jun 30, 2025

Nuveen LLC

2.54M

1.57%

+320.39K

+14.42%

Jun 30, 2025

Two Sigma Investments, LP

2.27M

1.41%

+455.53K

+25.08%

Jun 30, 2025

持股ETF



更新時間: 10月6日週一

機構名稱

佔比

SPDR S&P Pharmaceuticals ETF

2.8%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.04%

Virtus LifeSci Biotech Clinical Trials ETF

1.38%

Vanguard US Momentum Factor ETF

0.26%

iShares Micro-Cap ETF

0.24%

Even Herd Long Short ETF

0.24%

Federated Hermes MDT Small Cap Core ETF

0.18%

Fidelity Small-Mid Multifactor ETF

0.14%

ProShares Ultra Nasdaq Biotechnology

0.13%

Invesco Nasdaq Biotechnology ETF

0.13%

SPDR S&P Pharmaceuticals ETF

佔比2.8%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比2.04%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.38%

Vanguard US Momentum Factor ETF

佔比0.26%

iShares Micro-Cap ETF

佔比0.24%

Even Herd Long Short ETF

佔比0.24%

Federated Hermes MDT Small Cap Core ETF

佔比0.18%

Fidelity Small-Mid Multifactor ETF

佔比0.14%

ProShares Ultra Nasdaq Biotechnology

佔比0.13%

Invesco Nasdaq Biotechnology ETF

佔比0.13%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據